Piper Sandler Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD)

May 22, 2024 7:47 AM EDT Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $18.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login